{'fraction_non_alphanumeric': 0.03930530164533821, 'fraction_numerical': 0.048446069469835464, 'mean_word_length': 6.1568627450980395, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
More Vaccine Efficacy Studies on the Recombinant Bacille Calmette‐Guerin Co‐expressing Ag85B, Mpt64190–198 and Mtb8.4

The immunogenicity of the recombinant Bacille Calmette‐Guerin: rBCG‐Ag85B‐Mpt64190–198‐Mtb8.4 (rBCG‐AMM) was evaluated in our previous study. This paper compares the protective efficacy of rBCG‐AMM, rBCG‐A which overexpresses Ag85B and BCG in C57BL/6 mice. There was no significant difference in proliferation characteristics among rBCG‐AMM, rBCG‐A and BCG. The growth characteristics of rBCG‐AMM in host tissue were identical to control BCG, suggesting the improved protective efficacy was directly related to the expression of the Ag85B‐Mpt64190–198‐Mtb8.4 fusion protein. The protective experiment demonstrated that rBCG‐AMM could confer similar or even better protective efficacy against Mycobacterium tuberculosis infection compared with BCG or rBCG‐A as evaluated by bacterial organ loads, lung histopathology and net weight gain or loss. The results suggested that the recombinant BCG: rBCG‐Ag85B‐Mpt64190–198‐Mtb8.4 is a potential vaccine candidate for further study.